Home › Conditions › Pulmonary Embolism
Cardiology
Pulmonary Embolism
Risk stratify using the Wells PE score. Score >4: PE likely — CTPA immediately. Score ≤4: PE unlikely — D-dimer; if positive, CTPA. Massive PE (haemodynamic instability) requires immediate thrombolysis or catheter-directed therapy.
NICE Two-Level PE Pathway
The pathway
Wells PE score
- Clinical signs of DVT (+3)
- Alternative diagnosis less likely than PE (+3)
- HR >100 (+1.5)
- Immobilisation >3 days or surgery in previous 4 weeks (+1.5)
- Previous VTE (+1.5)
- Haemoptysis (+1)
- Cancer: on treatment, treated in last 6 months, or palliative (+1)
>4 = PE likely.
Immediate investigations
- ABG
- ECG (sinus tachycardia commonest; S1Q3T3 in massive PE)
- CXR
- CTPA if Wells >4 or D-dimer positive.
Oxygen
Give O₂ for hypoxaemia, titrated to 94–98% (88–92% if at risk of hypercapnic respiratory failure). Use high-concentration oxygen initially if critically ill.
Anticoagulation
Start immediately if high clinical suspicion and no contraindication. Do NOT wait for CTPA confirmation in massive PE.
Haemodynamic support
- If low filling pressure/hypovolaemia: cautious IV fluid challenge up to 500ml, reassessing; avoid further fluid if RV overloaded
- Noradrenaline via ICU if shocked
Massive PE
- Arrest or obstructive shock: act immediately; call ICU/cardiology for reperfusion
- Persistent SBP <90 or fall ≥40mmHg for >15min, excluding arrhythmia, hypovolaemia or sepsis, also indicates high risk
- Alteplase 10mg IV bolus then 90mg over 2h; if <65kg, total maximum 1.5mg/kg
- If lysis contraindicated: urgent surgical embolectomy/mechanical thrombectomy discussion
Long-term
- DOAC for 3 months minimum (NG158), then a review of whether to continue
- Extended treatment if unprovoked, or while cancer remains active
- No routine thrombophilia screen — NG158: not while anticoagulation continues, and not after a provoked VTE at all
- Antiphospholipid testing only in unprovoked VTE when stopping is being considered — the reviewing team's call
- A screen sent while anticoagulated is hard to interpret anyway
Drugs
| Drug | Dose | Route | Notes |
|---|---|---|---|
| Apixaban | 10mg BD for 7 days then 5mg BD | PO | First-line DOAC for PE. No bridging required. |
| Rivaroxaban | 15mg BD for 21 days then 20mg OD; both with food | PO | Alternative first-line DOAC. |
| LMWH (enoxaparin) | 1.5mg/kg OD or 1mg/kg BD | SC | Use if DOAC not suitable (e.g. pregnancy, or cancer with problematic bleeding risk/drug interactions). Cancer alone does not rule out a DOAC. |
| Alteplase | 10mg IV bolus then 90mg over 2h; if <65kg, reduce infusion for a total maximum of 1.5mg/kg | IV | Massive PE only. Stop anticoagulation during infusion. |
| Unfractionated heparin | 80 units/kg bolus then 18 units/kg/hr | IV | Use in massive PE before/after thrombolysis. |
When to escalate
Reference: NICE NG158 / ESC PE Guidelines 2019
Practise and explore
Practise a case or explore differentials here on the website. The optional browser app adds personal learning tools and saved progress.